

Effectiveness of an Immune-guided Cytomegalovirus Infection Preventive Strategy Compared to a Universal Prophylactic Strategy in Renal Transplant Patients

NCT05708508

Status	RECRUITING
Phase	Phase 3
Sponsor	University Hospital, Rouen
Enrollment	144 participants

Key Eligibility Criteria

Inclusion (5)

- Renal transplant patient for 1 to 12 days
- CMV seropositivity on the day of transplantation: IgG threshold =6 AU/mL CMIA CMV IgG, Architect i4000 (Abbott) (Serology performed on D0, before the transplant)
- Non-depleting inducing immunosuppressive treatment (Basiliximab) (implementation before the transplant)
- Affiliation to a social security scheme
- Patient having read and understood the information letter and signed the consent form

Exclusion (4)

- Active CMV infection (detectable CMV DNAemia - peripheral CMV DNAemia \geq 305 IU/mL)
- Patient with hypersensitivity to valganciclovir, ganciclovir, aciclovir or valaciclovir or to any of the excipients
- Lympho-depleting inducing immunosuppressive treatment (antithymoglobulins)
- Neutropenia (neutrophils $<$ 500/mm³) or thrombocytopenia (platelets $<$ 25,000/mm³) or anemia (hemoglobin $<$ 8G/L) identified on routine care samples taken on the day of inclusion

Locations (1 total)

Chu Rouen, Rouen, France